A Promising New Treatment for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of estrogen and progesterone receptors and HER2. Unlike other breast cancer subtypes, TNBC does not respond to hormonal or HER2-targeted therapies, making treatment options limited. Researchers have been investigating novel therapeutic approaches, including immunotherapies, to improve outcomes in metastatic TNBC.